Loading clinical trials...

Salivary Alpha Amylase as a Biomarker of Transdermal Vagus Nerve Stimulation | Clinical Trials | Clareo Health

COMPLETEDNANCT03854539

Salivary Alpha Amylase as a Biomarker of Transdermal Vagus Nerve Stimulation

The proposed project tests the hypothesis that salivary alpha amylase concentration is a reliable biomarker of the effect of transdermal vagus nerve stimulation (tVNS) in humans.

Lead sponsor: Arkansas Tech University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment100

Start dateMar 2018

Last updatedJun 18, 2020

Condition

No Condition Salivary Alpha Amylase

Locations shown

Arkansas Tech University

Russellville, Arkansas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 18, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions